The arrival of G7 health ministers to Oxford on Thursday 03 June will shine a spotlight on Oxfordshire’s considerable achievements in the life sciences sector.
Led by an existing investor, the funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma.